The changing epidemiology of meningococcal disease in North America 1945–2010

References

• van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849 - 59; http://dx.doi.org/10.1056/NEJMoa040845; PMID: 15509818
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases; 4th edition. Centers for Disease Control and Prevention. 2012.
   Google Scholar
• World Health Organisation. Meningococcal meningitis Fact sheet N°141. <http://www.who.int/mediacentre/factsheets/fs141/en/index.html>
   Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853 - 61; http://dx.doi.org/10.1016/S1473-3099(10)70251-6; PMID: 21075057
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarró M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011; 9:761 - 74; http://dx.doi.org/10.1586/eri.11.89; PMID: 21905785
   PubMed Web of Science ®Google Scholar
• Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19:142 - 64; http://dx.doi.org/10.1128/CMR.19.1.142-164.2006; PMID: 16418528
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010; 107:19490 - 5; http://dx.doi.org/10.1073/pnas.1013758107; PMID: 20962280
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:Suppl 2 B51 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.04.063; PMID: 19477562
   PubMed Web of Science ®Google Scholar
• Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010; 9:285 - 98; http://dx.doi.org/10.1586/erv.10.3; PMID: 20218857
   PubMed Web of Science ®Google Scholar
• Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010; 10:175; http://dx.doi.org/10.1186/1471-2334-10-175; PMID: 20565757
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184 - 91; http://dx.doi.org/10.1086/649209; PMID: 20001736
   PubMed Web of Science ®Google Scholar
• Hershey JH, Hitchcock W. Epidemiology and meningococcal serogroup distribution in the United States. Clin Pediatr (Phila) 2010; 49:519 - 24; http://dx.doi.org/10.1177/0009922809347797; PMID: 20507868
   PubMed Web of Science ®Google Scholar
• PHAC. Notifiable diseases online. <http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/index-eng.php> Accessed Apr. 2010.
   Google Scholar
• CDC. ABC surveillance reports. <http://www.cdc.gov/abcs/reports-findings/surv-reports.html> Accessed Oct. 2011.
   Google Scholar
• Bennet JV, Young LS. Trends in meningococcal disease. J Infect Dis 1969; 120:634 - 5; PMID: 5346539
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180:1894 - 901; http://dx.doi.org/10.1086/315158; PMID: 10558946
   PubMed Web of Science ®Google Scholar
• Schlech WF 3rd, Ward JI, Band JD, Hightower A, Fraser DW, Broome CV. Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study. JAMA 1985; 253:1749 - 54; http://dx.doi.org/10.1001/jama.1985.03350360075022; PMID: 3871869
   PubMed Web of Science ®Google Scholar
• Varughese PV. Meningococcal disease in Canada: surveillance summary to 1987. CMAJ 1989; 141:567 - 9; PMID: 2505917
   PubMed Web of Science ®Google Scholar
• Whalen CM, Hockin JC, Ryan A, Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA 1995; 273:390 - 4; http://dx.doi.org/10.1001/jama.1995.03520290042027; PMID: 7823384
   PubMed Web of Science ®Google Scholar
• Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50:Suppl 2 S37 - 44; http://dx.doi.org/10.1086/648963; PMID: 20144015
   PubMed Web of Science ®Google Scholar
• PHAC. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003. Can Commun Dis Rep 2006; 32:97 - 107; PMID: 16685767
   PubMedGoogle Scholar
• Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009; 28:220 - 4; http://dx.doi.org/10.1097/INF.0b013e31819040e7; PMID: 19209096
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011; 30:566 - 9; http://dx.doi.org/10.1097/INF.0b013e31820e8638; PMID: 21326136
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Weekly Epidemiological Record Year 20. <http://www.who.int/wer/archives/en/> Accessed May 2011.
   Google Scholar
• Wiggins GL, Hollis DG, Weaver R. Prevalence of serogroups and sulfonamide resistance of meningococci from the civilian population in the United States, 1964-1970. Am J Public Health 1973; 63:59 - 65; http://dx.doi.org/10.2105/AJPH.63.1.59; PMID: 4630078
   PubMed Web of Science ®Google Scholar
• Meningococcal Disease Surveillance Group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis 1976; 134:201 - 4; http://dx.doi.org/10.1093/infdis/134.2.201; PMID: 823273
   PubMed Web of Science ®Google Scholar
• Band JD, Chamberland ME, Platt T, Weaver RE, Thornsberry C, Fraser DW. Trends in meningococcal disease in the United States, 1975-1980. J Infect Dis 1983; 148:754 - 8; http://dx.doi.org/10.1093/infdis/148.4.754; PMID: 6313816
   PubMed Web of Science ®Google Scholar
• Varughese PV, Carter AO. Meningococcal disease in Canada and serogroup distribution. Can Dis Wkly Rep 1983; 9:177 - 80
   Google Scholar
• Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ 1993; 42:21 - 30; PMID: 8510639
   PubMedGoogle Scholar
• Tsang RSW, Squires SG, Zollinger WD, Ashton FE. Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can J Infect Dis 2002; 13:391 - 6; PMID: 18159416
   PubMedGoogle Scholar
• Fischer M, Perkins B. Neisseria meningitidis serogroup B: Emergence of the ET-5 complex. Semin Pediatr Infect Dis 1997; 8:50 - 6; http://dx.doi.org/10.1016/S1045-1870(97)80009-X
   Google Scholar
• Atkinson W, Wolfe S, Hamborsky J. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12 ed. Washington DC: Public Health Foundation. 2011.
   Google Scholar
• Tsang RSW, Henderson AM, Cameron ML, Tyler SD, Tyson S, Law DKS, et al. Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 2007; 45:1753 - 8; http://dx.doi.org/10.1128/JCM.02134-06; PMID: 17442798
   PubMed Web of Science ®Google Scholar
• Whitney AM, Coulson GB, von Gottberg A, Block C, Keller N, Mayer LW, et al. Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol 2009; 47:2787 - 93; http://dx.doi.org/10.1128/JCM.00091-09; PMID: 19571028
   PubMed Web of Science ®Google Scholar
• Advisory Committee Statement. An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/04vol30/dr3003a-eng.php. Can Commun Dis Rep 2001; 27: 2-36.
   Google Scholar
• Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, et al, Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011; 30:451 - 5; PMID: 21206392
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Mejia-Echeverry A, Fiorella P, Leguen F, Livengood J, Kay R, et al. Cluster of serogroup W135 meningococci, southeastern Florida, 2008-2009. Emerg Infect Dis 2010; 16:113 - 5; http://dx.doi.org/10.3201/eid1601.091026; PMID: 20031054
   PubMed Web of Science ®Google Scholar
• Advisory Committee Statement. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/04vol30/dr3003a-eng.php. Can Commun Dis Rep 2009; 35: 1-40.
   Google Scholar
• Havens PL, Garland JS, Brook MM, Dewitz BA, Stremski ES, Troshynski TJ. Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987. Pediatr Infect Dis J 1989; 8:8 - 11; http://dx.doi.org/10.1097/00006454-198901000-00003; PMID: 2922245
   PubMed Web of Science ®Google Scholar
• Feldman RA, Koehler RE, Fraser DW. Race-specific differences in bacterial meningitis deaths in the United States, 1962-1968. Am J Public Health 1976; 66:392 - 6; http://dx.doi.org/10.2105/AJPH.66.4.392; PMID: 1267089
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: Hospital case characteristics and costs by age. Value Health 2006; 9:236 - 43; http://dx.doi.org/10.1111/j.1524-4733.2006.00113.x; PMID: 16903993
   PubMed Web of Science ®Google Scholar
• Shepard CW, Rosenstein NE, Fischer M, Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990 to 1999. Pediatr Infect Dis J 2003; 22:418 - 22; http://dx.doi.org/10.1097/01.inf.0000066876.77453.04; PMID: 12792381
   PubMed Web of Science ®Google Scholar
• Squires SG, Pelletier L, Mungai M, Tsang R, Collins F, Stoltz J. Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998. Can Commun Dis Rep 2000; 26:177 - 82; PMID: 11107657
   PubMedGoogle Scholar
• Brooks R, Woods CW, Benjamin DK Jr., Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 2006; 43:49 - 54; http://dx.doi.org/10.1086/504804; PMID: 16758417
   PubMed Web of Science ®Google Scholar
• Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995; 273:383 - 9; http://dx.doi.org/10.1001/jama.1995.03520290035026; PMID: 7823383
   PubMed Web of Science ®Google Scholar
• Filice GA, Englender SJ, Jacobson JA, Jourden JL, Burns DA, Gregory D, et al. Group A meningococcal disease in skid rows: epidemiology and implications for control. Am J Public Health 1984; 74:253 - 4; http://dx.doi.org/10.2105/AJPH.74.3.253; PMID: 6198932
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunisation (NACI). An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 2001; 27:2 - 36; PMID: 11706686
   PubMedGoogle Scholar
• Squires SG, Deeks SL, Tsang RS. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 2004; 30:17 - 28; PMID: 14971276
   PubMedGoogle Scholar
• Tyrrell GJ, Chui L, Johnson M, Chang N, Rennie RP, Talbot JA, Edmonton Meningococcal Study Group. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 2002; 8:519 - 21; http://dx.doi.org/10.3201/eid0805.010337; PMID: 11996690
   PubMed Web of Science ®Google Scholar
• Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999; 281:1493 - 7; http://dx.doi.org/10.1001/jama.281.16.1493; PMID: 10227318
   PubMed Web of Science ®Google Scholar
• Law DKS, Lorange M, Ringuette L, Dion R, Giguère M, Henderson AM, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006; 44:2743 - 9; http://dx.doi.org/10.1128/JCM.00601-06; PMID: 16891487
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:RR-5 13 - 21; PMID: 9048847
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:794 - 5; PMID: 17694617
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72 - 6; PMID: 21270745
   PubMedGoogle Scholar
• Addendum. Update: guidelines for the prevention and control of meningococcal disease. Can Commun Dis Rep 2006; 32:270 - 2; PMID: 17115511
   PubMedGoogle Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 2005; 116:496 - 505; http://dx.doi.org/10.1542/peds.2005-1314; PMID: 15995007
   PubMed Web of Science ®Google Scholar
• De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285:177 - 81; http://dx.doi.org/10.1001/jama.285.2.177; PMID: 11176810
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004; 292:2491 - 4; http://dx.doi.org/10.1001/jama.292.20.2491; PMID: 15562128
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737 - 43; http://dx.doi.org/10.1086/527401; PMID: 18271745
   PubMed Web of Science ®Google Scholar
• CDC. MCV4 1 or more doses. <http://www.cdc.gov/vaccines/stats-surv/nisteen/figures/2008_map.htm> Accessed Apr. 2010.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:1100 - 3; PMID: 18846032
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1117 - 23; PMID: 21866084
   PubMedGoogle Scholar
• National Advisory Committee on Immunization (NACI). Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007; 33:ACS-11 1 - 12; PMID: 18064747
   PubMedGoogle Scholar
• PHAC. Advice for consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine, for use by provinces and territories. Can Commun Dis Rep 2010; 36
   Google Scholar
• Siu T, Tang W, Dawar M, Patrick DM. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia. Can J Public Health 2008; 99:380 - 2; PMID: 19009920
   PubMed Web of Science ®Google Scholar
• Lingappa JR, Al-Rabeah AM, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003; 9:665 - 71; http://dx.doi.org/10.3201/eid0906.020565; PMID: 12781005
   PubMed Web of Science ®Google Scholar
• Mueller JE, Borrow R, Gessner BD. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev Vaccines 2006; 5:319 - 36; http://dx.doi.org/10.1586/14760584.5.3.319; PMID: 16827617
   PubMed Web of Science ®Google Scholar
• Efron AM, Sorhouet C, Salcedo C, Abad R, Regueira M, Vázquez JA. W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. J Clin Microbiol 2009; 47:1979 - 80; http://dx.doi.org/10.1128/JCM.02390-08; PMID: 19357205
   PubMed Web of Science ®Google Scholar
• Cohn A. Optimizing the adolescent meningococcal vaccination program. <http://www.cdc.gov/vaccines/recs/acip/slides-oct10.htm#mening> Accessed Feb. 2011.
   Google Scholar